MedTrace Logo

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

NCT01437982 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2019-11-19

No results posted yet for this study

Summary

The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice

Conditions

  • Conjunctivitis, Seasonal Allergic
  • Conjunctivitis, Giant Papillary
  • Inflammation

Interventions

DRUG

Loteprednol Etabonate

Ocular administration of study drug. at least once within any indication of the label.

DRUG

Prednisolone Acetate 1% Oph Susp

Ocular administration of study drug. at least once within any indication of the label.

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Binu Alexander, MD · Valeant Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-05
Primary Completion
2015-10-19
Completion
2015-10-19

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01437982 on ClinicalTrials.gov